

\$%^Dialog;HighlightOn=*;HighlightOff=*;

Connecting via Winsock to Dialog

Logging in to Dialog

Trying 3106000009998...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

ENTER PASSWORD:

Welcome to DIALOG

Dialog level 04.11.00D

Last logoff: 20may04 12:57:14

Logon file405 01jul04 11:43:31

*** ANNOUNCEMENT ***

--File 654 - US published applications from March 15, 2001 to the present are now online. Please see HELP NEWS 654 for details.

--File 581 - The 2003 annual reload of Population Demographics is complete. Please see Help News581 for details.

--File 990 - NewsRoom now contains February 2004 to current records.
File 992 - NewsRoom 2003 archive has been newly created and contains records from January 2003. The oldest months's records roll out of File 990 and into File 992 on the first weekend of each month.
To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new OneSearch category.

--Connect Time joins DialUnits as pricing options on Dialog. See HELP CONNECT for information.

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

--Important Notice to Freelance Authors--
See HELP FREELANCE for more information

NEW FILES RELEASED

***MetalBase (File 36)

***AeroBase (File 104)

***DIOGENES: Adverse Drug Events Database (File 181)

***World News Connection (File 985)

***Dialog NewsRoom - 2003 Archive (File 992)

***TRADEMARKSCAN-Czech Republic (File 680)

***TRADEMARKSCAN-Hungary (File 681)

***TRADEMARKSCAN-Poland (File 682)

UPDATING RESUMED

RELOADED

***Toxfile (File 156)

***Medline (Files 154-155)

***Population Demographics -(File 581)

***CLAIMS Citation (Files 220-222)

REMOVED

>>> Enter BEGIN HOMEBASE for Dialog Announcements
<<<

>>> of new databases, price changes, etc. <<<

HILIGHT set on as '*'

KWIC is set to 50.

* * * *

SYSTEM:HOME

Cost is in DialUnits

Menu System II: D2 version 1.7.9 term=ASCII

*** DIALOG HOMEBASE(SM) Main Menu ***

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help /L = Logoff /NOMENU =
Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).
? b 410

01jul04 11:43:33 User217743 Session D640.1
\$0.00 0.164 DialUnits FileHomeBase
\$0.00 Estimated cost FileHomeBase
\$0.00 Estimated cost this search
\$0.00 Estimated total session cost 0.164 DialUnits

File 410:Chronolog(R) 1981-2004/May
(c) 2004 The Dialog Corporation

Set Items Description

--- -----
? set hi *;set hi *
HIGHLIGHT set on as '*'*
HIGHLIGHT set on as ''*
? b 155
01jul04 11:43:41 User217743 Session D640.2
\$0.00 0.078 DialUnits File410
\$0.00 Estimated cost File410
\$0.03 TELNET
\$0.03 Estimated cost this search
\$0.03 Estimated total session cost 0.242 DialUnits

File 155:MEDLINE(R) 1966-2004/Jun W2
(c) format only 2004 The Dialog Corp.
*File 155: Medline has been reloaded. Accession numbers
have changed. Please see HELP NEWS 154 for details.

Set Items Description

--- -----
? s infliximab
S1 1282 INFLIXIMAB
? s etanercept
S2 559 ETANERCEPT
? s s1 or s2
1282 S1
559 S2
S3 1591 S1 OR S2
? s s3 and (immobilize? or solid())support or affinity)
1591 S3
26568 IMMOBILIZE?
79595 SOLID
3620501 SUPPORT
1214 SOLID(W)SUPPORT
183087 AFFINITY
S4 9 S3 AND (IMMOBILIZE? OR
SOLID())SUPPORT OR AFFINITY)
? t s4/3,ab/all

4/3,AB/1
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

15841502 PMID: 14632813
Infliximab for hidradenitis suppurativa.
Sullivan T P; Welsh E; Kerdel F A; Burdick A E; Kirsner R
S

Department of Dermatology and Cutaneous Surgery,
University of Miami
School of Medicine/Cedars Medical Center, 1400 NW
12th Ave. 6 South
Dermatology, Miami, FL 33136, USA.

British journal of dermatology (England) Nov 2003, 149
(5) p1046-9,
ISSN 0007-0963 Journal Code: 0004041

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

BACKGROUND: Hidradenitis suppurativa (HS) is a
chronic disease
characterized by significant morbidity. Current medical
therapies are only
minimally effective at treating the disease. *Infliximab* is
a chimeric
monoclonal antibody with high *affinity* for tumour
necrosis factor
(TNF)-alpha. TNF-alpha is known to induce
proinflammatory cytokines and may
play an important role in the therapy of a number of
disparate inflammatory
disorders. *Infliximab* has shown promise for the therapy
of rheumatoid
arthritis and psoriasis. OBJECTIVES: Retrospectively
to evaluate the
effectiveness of *infliximab* for the treatment of HS.
METHODS: A
retrospective chart review was performed for
patients who received
infliximab at the University of Miami Department of
Dermatology.
Patients were contacted and asked retrospectively to
rate their disease
activity immediately prior to and after therapy.
RESULTS: Patients'
self-reported disease activity scores were significantly
decreased (P =
0.0001, paired t-test) following *infliximab* infusion. This
correlated
with physician-observed clinical improvement.
CONCLUSIONS: *Infliximab*
is a promising agent for the treatment of HS. These initial
results suggest
that *infliximab* is associated with objective and
subjective
improvement in HS. Further controlled studies of the
efficacy of
infliximab and its effect on the course of the disease
are warranted.

4/3,AB/2
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

15008755 PMID: 12171504

Soluble cytokine receptors in biological therapy.
Fernandez-Botran Rafael; Crespo Fabian A; Sun Xichun
Department of Pathology & Laboratory Medicine,
School of Medicine,
University of Louisville, Louisville, KY 40292, USA.
Rafael@louisville.edu

Expert opinion on biological therapy (England) Aug
2002, 2 (6)

p585-605, ISSN 1471-2598 Journal Code: 101125414

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Data Review

Due to their fundamental involvement in the
pathogenesis of many

diseases, cytokines constitute key targets for
biotherapeutic approaches.

The discovery that soluble forms of cytokine receptors
are involved in the

endogenous regulation of cytokine activity has
prompted substantial

interest in their potential application as

immunotherapeutic agents. As

such, soluble cytokine receptors have many
advantages, including

specificity, low immunogenicity and high *affinity* .
Potential

disadvantages, such as low avidity and short in vivo half-
lives, have been

addressed by the use of genetically-designed receptors,
hybrid proteins or

chemical modifications. The ability of many soluble
cytokine receptors to

inhibit the binding and biological activity of their ligands
makes them

very specific cytokine antagonists. Several

pharmaceutical companies have

generated a number of therapeutic agents based on
soluble cytokine

receptors and many of them are undergoing clinical
trials. The most

advanced in terms of clinical development is

etanercept (Enbrel,

Immunex), a fusion protein between soluble TNF receptor
Type II and the Fc

region of human IgG1. This TNF-alpha; antagonist was
the first soluble

cytokine receptor to receive approval for use in humans.
In general, most

agents based on soluble cytokine receptors have been
safe, well-tolerated

and have shown only minor side effects in the majority of
patients. Soluble

cytokine receptors constitute a new generation of
therapeutic agents with

tremendous potential for applications in a wide variety of
human diseases.

Two current areas of research are the identification
of their most
promising applications and characterisation of their long-
term effects.

4/3,AB/3

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

15008454 PMID: 12110154

How does *infliximab* work in rheumatoid arthritis?

Maini Ravinder N; Feldmann Marc

The Kennedy Institute of Rheumatology Division,
Imperial College of

Science Technology and Medicine, London, UK.

r.maini@ic.ac.uk

Arthritis research (England) 2002, 4 Suppl 2 pS22-8,
ISSN 1465-9905

Journal Code: 100913255

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Data Review

Since the initial characterization of tumor necrosis
factor alpha

(TNFalpha), it has become clear that TNFalpha has
diverse biologic

activity. The realization that TNFalpha plays a role in
rheumatoid

arthritis (RA) has led to the development of anti-TNF
agents for the

treatment of RA. *Infliximab* , a chimeric monoclonal
antibody that

specifically, and with high *affinity* , binds to
TNFalpha and

neutralizes the cytokine, is currently approved for the
treatment of RA and

Crohn's disease, another immune-inflammatory disorder.
In addition to

establishing the safety and efficacy of *infliximab* ,
clinical research

has also provided insights into the complex cellular and
cytokine-dependent

pathways involved in the pathophysiology of RA,
including evidence that

supports TNFalpha involvement in cytokine regulation,
cell recruitment,

angiogenesis, and tissue destruction.

4/3,AB/4

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12628340 PMID: 7538333

The mouse/human chimeric monoclonal antibody cA2
neutralizes TNF in vitro

and protects transgenic mice from cachexia and TNF lethality in vivo.

Siegel S A; Shealy D J; Nakada M T; Le J; Woulfe D S; Probert L; Kollias

G; Ghrayeb J; Vilcek J; Daddona P E

Department of Immunology, Centocor, Inc., Malvern PA 19355, USA.

Cytokine (UNITED STATES) Jan 1995, 7 (1) p15-25, ISSN 1043-4666

Journal Code: 9005353

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The pleiotropic cytokine tumour necrosis factor-alpha (TNF) is thought to play a central role in infectious, inflammatory and autoimmune diseases. Critical to the understanding and management of TNF-associated pathology is the development of highly specific agents capable of modifying TNF activity. We evaluated the ability of a high *affinity* mouse/human chimeric anti-TNF monoclonal antibody (cA2) to neutralize the in vitro and in vivo biological effects of TNF. cA2 inhibited TNF-induced mitogenesis and IL-6 secretion by human fibroblasts, TNF-priming of human neutrophils, and the stimulation of human umbilical vein endothelial cells by TNF as measured by the expression of E-selectin, ICAM-1 and procoagulant activity. cA2 also specifically blocked TNF-induced adherence of human neutrophils to an endothelial cell monolayer. Receptor binding studies suggested that neutralization resulted from cA2 blocking of TNF binding to both p55 and p75 TNF receptors on the cells. In vivo, repeated administration of cA2 to transgenic mice that constitutively express human TNF reversed the cachectic phenotype and prevented subsequent mortality. These results demonstrated that cA2 effectively neutralized a broad range of TNF biological activities both in vitro and in vivo.

4/3,AB/5

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12055469 PMID: 12379627

Infliximab treatment for rheumatic disease: clinical and

radiological efficacy.

St Clair E W

Department of Medicine, Division of Rheumatology, Duke University Medical

Center, Durham, NC, USA. stcla003@mc.duke.edu

Annals of the rheumatic diseases (England) Nov 2002, 61 Suppl 2

pii67-9, ISSN 0003-4967 Journal Code: 0372355

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Infliximab is a chimeric anti-tumour necrosis factor alpha (TNFalpha) monoclonal antibody with high *affinity* and binding specificity for human TNFalpha. Results from several well designed, controlled clinical trials show repeated infusions of *infliximab* with concomitant methotrexate (MTX) treatment can reduce the signs and symptoms of rheumatoid arthritis (RA). This combination of *infliximab* and MTX also slows the radiological progression of joint damage, decreases functional disability, and improves quality of life. These remarkably positive results have led to the investigation of *infliximab* treatment for other rheumatic diseases. Recently, controlled studies have shown treatment with *infliximab* can benefit patients with active spondyloarthritis. TNFalpha has fast become an important therapeutic target in rheumatology.

4/3,AB/6

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11423402 PMID: 11520249

New therapeutic approaches to the management of rheumatoid arthritis.

Hughes L B; Moreland L W

Department of Medicine, Division of Clinical Immunology and Rheumatology,

University of Alabama at Birmingham, 1813 6th Ave South, Birmingham, AL

35294, USA. Laura.Hughes@ccc.uab.edu

BioDrugs - clinical immunotherapeutics,

biopharmaceuticals and gene

therapy (New Zealand) 2001, 15 (6) p379-93, ISSN

1173-8804

Journal Code: 9705305

Document type: Journal Article

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Rheumatoid arthritis (RA) is a common disease that affects up to 1% of the population, and causes significant morbidity and early mortality. The aetiology of RA is unknown; however, in the last 10 to 15 years significant advances in molecular technology have provided a greater understanding of the pathogenesis of the disease. This has led to the development of new approaches to the treatment of RA. The disease modifying antirheumatic oral agent leflunomide inhibits the proliferation of activated T cells that are important in the inflammation and degradation of synovial tissues. The 2 biological agents approved for the treatment of RA, *infliximab* and *etanercept*, are inhibitors of the pro-inflammatory cytokine, tumour necrosis factor-alpha (TNFalpha). *Infliximab* is a chimeric human/mouse monoclonal antibody which is administered by intravenous infusion and binds with high *affinity* to TNFalpha, thereby neutralising its effects. *Etanercept* is a recombinant, soluble TNF receptor molecule which is administered subcutaneously and binds to TNFalpha in the serum rendering it biologically inactive. The protein A immunoadsorption column is a medical device that in conjunction with plasmapheresis can be used in patients with refractory RA. These agents have provided new and effective therapies for the treatment of patients with RA.

4/3,AB/7
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

11367282 PMID: 11458980

Immunomodulatory effects of *etanercept* (TNFR:Fc) and its use in a patient with Crohn's disease.

Srivastava M D
Department of Pediatrics, MetroHealth Medical Center, Cleveland, Ohio 44109, USA.

Research communications in molecular pathology and pharmacology (United

States) Jul 2001, 109 (1-2) p125-41, ISSN 1078-0297 Journal Code: 9437512

Document type: Case Reports; Clinical Trial; Journal Article

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Designer drug *etanercept* (TNFR:Fc) is an inhibitor of TNF-alpha that binds with greater *affinity* than membrane receptors. Its full immunomodulatory effects are unknown. Approved for rheumatoid arthritis, its therapeutic potential in Crohn's disease has yet to be explored. We describe the course of a steroid-dependent patient with Crohn's disease given *etanercept*, and its effects on cytokine protein and mRNA expression and transcription factor activity in human leukocytes.

Etanercept 25 mg s.c., was given twice weekly for 1 month. Weekly ESR, disease activity index, prednisone requirement, and serum cytokines were determined. In vitro, effects of physiologic concentrations of *etanercept* on cytokine protein and mRNA, and NFkB and GR transcription factor activity, were determined using MOT and U937 cell lines and peripheral blood mononuclear cells. Rapid clinical, biochemical, and immunologic improvement occurred, but obstruction due to stricture developed after 4 weeks. In vitro, constitutive and stimulated production of TNF-beta, IL-1beta, MIP-1beta, and IL-8 by normal mononuclear cells declined with *etanercept*, detectable TNF-alpha increased. MOT TNF-alpha expression tripled, mRNA for IL-12 p40 doubled, GR activity declined in U937 cells, NFkB was unaffected. *Etanercept* has complex immunomodulatory effects, and may be useful in Crohn's disease, but acutely decreased inflammation could worsen stricture.

4/3,AB/8
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

11209364 PMID: 11249494

Tumour necrosis factor-alpha blockade: a new era for effective management

of rheumatoid arthritis.

Hamilton K; Clair E W

Division of Rheumatology, Allergy and Clinical Immunology, Department of Medicine, Duke University Medical Centre, Durham, NC 27710, USA.

Expert opinion on pharmacotherapy (England) Jul 2000, 1 (5) p1041-52

, ISSN 1465-6566 Journal Code: 100897346

Document type: Journal Article; Review; Review, Tutorial Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Tumour necrosis factor (TNF)-alpha inhibitors have emerged as a new treatment option for rheumatoid arthritis (RA). The scientific rationale for targeting TNF-alpha in RA derives from extensive work in the laboratory, showing the importance of this pro-inflammatory cytokine as a mediator of joint inflammation. Proof of principle has now been firmly established in clinical trials where TNF-alpha inhibitors have been shown to decrease the signs and symptoms of joint inflammation and slow radiological progression of joint damage. Presently, the two TNF-alpha inhibitors available for use in RA are *etanercept* and *infliximab*. *Etanercept* is a soluble TNF receptor: Fc fusion protein that competes with the endogenous TNF receptors for TNF-alpha binding. *Infliximab* is a chimeric anti-TNF-alpha monoclonal antibody, which also binds with high *affinity* to soluble TNF-alpha. *Etanercept* and *infliximab* will be rapidly incorporated into current treatment paradigms, which call for early and intensive treatment of RA using disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, sulfasalazine and hydroxychloroquine. A major drawback to the widespread use of these biologics is their high costs. Some patients with limited financial means may be denied access to these effective anti-inflammatory agents. Moreover, long-term experience with TNF-alpha inhibitor therapy has been limited and concerns linger about the possibility that *etanercept* and *infliximab* may cause unforeseen

side effects or increase the risk for opportunistic infection. Despite these caveats, TNF-alpha inhibitors represent a major advance for the treatment of RA and will likely spawn new indications for anti-TNF-alpha therapy and the development of novel therapeutic compounds with similar biological activity.

4/3,AB/9

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

10921458 PMID: 11060691

Soluble cytokine receptors: novel immunotherapeutic agents.

Fernandez-Botran R

Departments of Pathology & Laboratory Medicine and Microbiology & Immunology, School of Medicine, University of Louisville, Louisville, KY 40292, USA.

Expert opinion on investigational drugs (ENGLAND) Mar 2000, 9 (3)

p497-514, ISSN 1354-3784 Journal Code: 9434197

Document type: Journal Article; Review; Review, Academic

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Being mediators of immune and inflammatory reactions, abnormal or excessive production of cytokines is often the main cause of the pathology in many types of disease. Targeting cytokines by means of inhibitory drugs may thus offer a valid therapeutic approach in particular diseases. Soluble forms of cytokine receptors (sCR) normally participate in the control of cytokine activity in vivo by inhibiting the ability of cytokines to bind their membrane receptors and from generating a biological response. The ability of sCR to act as cytokine inhibitors, coupled to their specificity, high affinities and low immunogenicities have prompted considerable interest in their use as immunotherapeutic agents. In fact, many types of sCR have been shown to inhibit the biological activity of their cytokines in vitro and in different experimental models. Several sCR, particularly the soluble TNF receptors sTNFR-I (p55) and sTNFR-II (p75), have been

modified by linking them to the Fc portion of human immunoglobulin (e.g., 'immunoadhesins') or by the addition of polyethylene-glycol (PEG) (e.g., 'PEGylation'), in order to enhance their *affinity* and/or biological half-life. These agents have shown significant therapeutic value in clinical trials of patients with rheumatoid arthritis (RA). Indeed, a sTNFR-II:Fc hybrid molecule (*etanercept*), the first sCR-derived therapeutic agent to receive approval for human use, is already utilised for the treatment of some forms of RA. Additional applications of this drug in other inflammatory conditions are currently being evaluated, while another sCR-derived agent, a human sIL-4R, is undergoing trials for the treatment of asthma. Many other sCR, such as sIL-1R, sIL-5R, sIFNgammaR, may also have significant potential for the treatment of a wide variety of human diseases.

? ds

Set	Items	Description
S1	1282	INFLIXIMAB
S2	559	ETANERCEPT
S3	1591	S1 OR S2
S4	9	S3 AND (IMMOBILIZE? OR SOLID())SUPPORT OR AFFINITY)

? s s3 and serum

1591 S3

514330 SERUM

S5 81 S3 AND SERUM

? s s5 and ex()vivo

81 S5

22634 EX

348124 VIVO

15309 EX(W)VIVO

S6 0 S5 AND EX()VIVO

? s s5 and dialyze

81 S5

65 DIALYZE

S7 0 S5 AND DIALYZE

? s s5 and dialysis

81 S5

86686 DIALYSIS

S8 1 S5 AND DIALYSIS

? t s8/3,ab/

8/3,AB/1

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11345614 PMID: 11434729

Treatment of complicated sarcoidosis with *infliximab* anti-tumor

necrosis factor-alpha therapy.

Yee A M; Pochapin M B

Hospital for Special Surgery and New York

Presbyterian Hospital, Weill

Medical College of Cornell University, New York, New York, USA.

Annals of internal medicine (United States) Jul 3

2001, 135 (1)

p27-31, ISSN 0003-4819 Journal Code: 0372351

Comment in Ann Intern Med. 2002 Aug 20;137(4) 296-7;

author reply 296-7;

Comment in PMID 12186527; Comment in Ann Intern

Med. 2002 Aug

20;137(4):296-7; author reply 296-7; Comment in PMID

12186528

Document type: Case Reports; Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha)

may have an important

role in the clinical exacerbation of sarcoidosis.

OBJECTIVE: To treat

sarcoidosis with *infliximab*, a chimeric human-murine

anti-human

TNF-alpha monoclonal antibody. DESIGN: Case report.

SETTING: U.S. academic

medical center. PATIENT: A 72-year-old woman with

sarcoidosis presenting

with severe protein-losing enteropathy,

hypoalbuminemia, and proximal

myopathy who had not responded adequately to

corticosteroid therapy and

whose clinical course was further complicated by acute

tubular necrosis and

renal failure requiring long-term hemodialysis.

INTERVENTION: Intravenous

infusion of *infliximab*, 5 mg/kg of ideal body weight;

infusion was

repeated at 2 and 6 weeks. MEASUREMENTS: Clinical

response of enteropathic

and myopathic symptoms and *serum* albumin level.

RESULTS: Enteropathic

and myopathic symptoms resolved after *infliximab*

therapy, and the

serum albumin level also improved. However, the clinical

course was

complicated by the development of a hypercoagulable

state associated with

circulating anticardiolipin antibodies, which prompted

discontinuation of

infliximab therapy. CONCLUSIONS: *Infliximab*

therapy was

successful in a patient with sarcoidosis. Tumor necrosis

factor-alpha may

be an important mediator of clinical disease in sarcoidosis and could be an attractive target for therapeutic intervention. However, *infliximab* may cause adverse effects associated with cytokine cascade manipulation.
 ? t s8/kwic/

8/KWIC/1
 DIALOG(R)File 155:(c) format only 2004 The Dialog Corp.
 All rts. reserv.

Treatment of complicated sarcoidosis with *infliximab* anti-tumor necrosis factor-alpha therapy.
 BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) may have an important role in the clinical exacerbation of sarcoidosis.
 OBJECTIVE: To treat sarcoidosis with *infliximab* , a chimeric human-murine anti-human TNF-alpha monoclonal antibody. DESIGN: Case report.
 SETTING: U.S. academic medical center. PATIENT: A 72-year-old woman...

... to corticosteroid therapy and whose clinical course was further complicated by acute tubular necrosis and renal failure requiring long-term hemodialysis. INTERVENTION: Intravenous infusion of *infliximab* , 5 mg/kg of ideal body weight; infusion was repeated at 2 and 6 weeks.
 MEASUREMENTS: Clinical response of enteropathic and myopathic symptoms and *serum* albumin level. RESULTS: Enteropathic and myopathic symptoms resolved after *infliximab* therapy, and the *serum* albumin level also improved. However, the clinical course was complicated by the development of a hypercoagulable state associated with circulating anticardiolipin antibodies, which prompted discontinuation of *infliximab* therapy. CONCLUSIONS: *Infliximab* therapy was successful in a patient with sarcoidosis. Tumor necrosis factor-alpha may be an important mediator of clinical disease in sarcoidosis and could be an attractive target for therapeutic intervention. However, *infliximab* may cause adverse effects associated with cytokine cascade manipulation.
 ...; Lung Diseases--complications--CO; Muscle Weakness--complications--CO

; Muscle Weakness--drug therapy--DT; Protein-Losing Enteropathies
 --complications--CO; Protein-Losing Enteropathies--drug therapy--DT; Renal
 Dialysis; Sarcoidosis--blood--BL; Sarcoidosis--complications--CO;
 Serum Albumin--metabolism--ME; Thrombosis--chemically induced--CI
 Chemical Name: Antibodies, Monoclonal; *Serum* Albumin; Tumor
 Necrosis Factor; *infliximab*
 ? s s5 and (ultrafiltration or ultrapheresis)

81 S5
 10931 ULTRAFILTRATION
 4 ULTRAPHERESIS
 S9 0 S5 AND (ULTRAFILTRATION OR ULTRAPHERESIS)
 ? s s5 and apheresis
 81 S5
 2691 APHERESIS
 S10 0 S5 AND APHERESIS
 ? b 411
 01jul04 11:53:08 User217743 Session D640.3
 \$4.54 1.417 DialUnits File155
 \$0.05 1 Type(s) in Format 95 (KWIC)
 \$2.10 10 Type(s) in Format 4 (UDF)
 \$2.15 11 Types
 \$6.69 Estimated cost File155
 \$2.49 TELNET
 \$9.18 Estimated cost this search
 \$9.21 Estimated total session cost 1.659 DialUnits
 File 411:DIALINDEX(R)

DIALINDEX(R)
 (c) 2004 The Dialog Corporation plc
 *** DIALINDEX search results display in an abbreviated ***
 *** format unless you enter the SET DETAIL ON command. ***
 ? set files biochem
 >>> 162 is unauthorized
 >>>1 of the specified files is not available
 You have 21 files in your file list.
 (To see banners, use SHOW FILES command)
 ? s (etanercept or infliximab) and apheresis
 Your SELECT statement is:
 s (etanercept or infliximab) and apheresis

Items	File
2	34: SciSearch(R) Cited Ref Sci_1990-2004/Jun W4
12	73: EMBASE_1974-2004/Jun W4
2	155: MEDLINE(R)_1966-2004/Jun W2

3 files have one or more items; file list includes 21 files.

? rf

Your last SELECT statement was:

S (ETANERCEPT OR INFLIXIMAB) AND APHERESIS

Ref	Items	File
---	-----	----
N1	12	73: EMBASE_1974-2004/Jun W4
N2	2	34: SciSearch(R) Cited Ref Sci_1990-2004/Jun W4
N3	2	155: MEDLINE(R)_1966-2004/Jun W2
N4	0	5: Biosis Previews(R)_1969-2004/Jun W4
N5	0	6: NTIS_1964-2004/Jun W4
N6	0	40: Enviroline(R)_1975-2004/May
N7	0	50: CAB Abstracts_1972-2004/May
N8	0	65: Inside Conferences_1993-2004/Jun W4
N9	0	71: ELSEVIER BIOBASE_1994-2004/Jun W3
N10	0	94: JICST-EPlus_1985-2004/Jun W1

3 files have one or more items; file list includes 21 files.

- Enter P or PAGE for more -

? b n3, n1

01jul04 11:54:09 User217743 Session D640.4

\$0.57 0.254 DialUnits File411

\$0.57 Estimated cost File411

\$0.50 TELNET

\$1.07 Estimated cost this search

\$10.28 Estimated total session cost 1.914 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2004/Jun W2

(c) format only 2004 The Dialog Corp.

*File 155: Medline has been reloaded. Accession numbers have changed. Please see HELP NEWS 154 for details.

File 73:EMBASE 1974-2004/Jun W4

(c) 2004 Elsevier Science B.V.

Set Items Description

--- -----

? s (etanercept or infliximab) and apheresis

2611 ETANERCEPT

4228 INFLIXIMAB

5977 APHERESIS

S1 14 (ETANERCEPT OR INFLIXIMAB) AND APHERESIS

? rd

...completed examining records

S2 13 RD (unique items)

? t s2/3,ab/all

2/3,AB/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

16254114 PMID: 14727131

Medical approaches and future options in chronic active ulcerative colitis.

Siveke J T; Folwaczny C

II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

International journal of colorectal disease (Germany) Jul 2004, 19

(4) p297-307, ISSN 0179-1958 Journal Code: 8607899

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Data Review

BACKGROUND. Immunosuppressive therapy employing purine analogues is the

therapeutic mainstay in patients with chronic active ulcerative colitis.

However, despite therapeutic optimization according to

thiopurine-methyltransferase activity or red blood cell 6-thioguanine

levels, a substantial proportion of patients does not tolerate azathioprine

or 6-mercaptopurine or relapses during this treatment. In the latter

multiple therapeutic regimens comprising 6-thioguanine, cyclosporin or

tacrolimus, methotrexate, cyclophosphamide, *infliximab*, interferons,

heparin, leukocyte *apheresis*, and various other regimens might be

considered aiming at long-term remission. Many of these treatment forms

have only been evaluated in small mostly uncontrolled trials. OBJECTIVE. In

this review existing treatment modalities and future options for patients

with chronic active ulcerative colitis will be discussed focusing on

immunomodulating approaches.

2/3,AB/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11275455 PMID: 11354293

Cost-effectiveness of Prosorba column therapy for rheumatoid arthritis: a framework for analysis.

Griffiths R I; Slurzberg J E

Project HOPE Center for Health Affairs, Bethesda, Maryland 20814-6133, USA. rgriffiths@projhope.org

Therapeutic apheresis - official journal of the International Society for

Apheresis and the Japanese Society for Apheresis (United States) Apr 2001
, 5 (2) p105-10, ISSN 1091-6660 Journal Code:
9706703

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Apheresis with the Prosorba column is safe and effective for treating refractory rheumatoid arthritis. It also is resource intensive. Economic evaluation of Prosorba column therapy could help promote efficient use of this technology. This article describes a framework and the data requirements for analyzing the cost-effectiveness of Prosorba column therapy. Several factors are considered in developing the framework including the target patient population, treatment alternatives, and clinical, economic, and quality of life outcomes of alternative treatments. We propose decision modeling as the appropriate study design because it provides a flexible framework for combining and analyzing data from different sources including experimental and nonexperimental studies. The cost-effectiveness of Prosorba column therapy will depend on the patient population in which it is used and the other treatment options still available to these patients. Offsets to the costs of providing Prosorba column therapy are likely to be largest in treatment-refractory patients and when this therapy is compared to other expensive new agents such as *etanercept*.

2/3,AB/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

12212177 EMBASE No: 2003319719
Investigational therapies for psoriasis
Cather J.C.; Cather J.C.; Abramovits W.
Dr. J.C. Cather, 5310 Harvest Hill, Dallas, TX 75230
United States
AUTHOR EMAIL: research@texasderm.com
Journal of the American Academy of Dermatology (J.
AM. ACAD. DERMATOL.)
(United States) 01 AUG 2003, 49/2 A (S133-S138)
CODEN: JAADD ISSN: 0190-9622
DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE:
ENGLISH
NUMBER OF REFERENCES: 48

As the pathogenesis of psoriasis is better understood, specific targeted therapies are being developed. In addition to alefacept, *etanercept*, efalizumab, and *infliximab*, discussed in separate articles in this issue, numerous other investigational therapies are currently in clinical trials, some of which will likely be approved in the future. We review the most promising of these therapies and their mechanisms of action.

2/3,AB/4 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

12193654 EMBASE No: 2003304874
Islet transplants and impact on secondary diabetic complications: Does C-peptide protect the kidney?
Shapiro A.M.J.
Dr. A.M.J. Shapiro, Clinical Islet Transplant Program, University of Alberta, 2000 College Plaza, 8215 112 Street, Edmonton, Alta. T6G 2C8
Canada
AUTHOR EMAIL: amjs@islet.ca
Journal of the American Society of Nephrology (J. AM. SOC. NEPHROL.) (United States) 01 AUG 2003, 14/8 (2214-2216)
CODEN: JASNE ISSN: 1046-6673
DOCUMENT TYPE: Journal ; Editorial
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 39

2/3,AB/5 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

12010223 EMBASE No: 2003120768
Novel therapies in the treatment of ulcerative colitis
Tulvin J.A.; Kane S.V.
S.V. Kane, Department of Medicine, Division of Gastroenterology, University of Chicago, 5841 South Maryland Ave., Chicago, IL 60637
United States
AUTHOR EMAIL: skane@medicine.bsd.uchicago.edu
Expert Opinion on Investigational Drugs (EXPERT OPIN. INVEST. DRUGS) (United Kingdom) 01 MAR 2003, 12/3 (483-490)

CODEN: EOIDE ISSN: 1354-3784
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE:
ENGLISH
NUMBER OF REFERENCES: 78

Ulcerative colitis is a chronic inflammatory disease of the colon of unknown cause. Its course is one of relapse and remission and requires therapy for both the induction and maintenance of remission. Progress in the fields of genetics and immunology affords important advances in our understanding of the inflammatory process. Traditional therapy for ulcerative colitis with nonspecific anti-inflammatories remains our gold standard. This review examines the most recent compounds in development for the treatment of ulcerative colitis, including data from early clinical trials and the potential clinical impact of future entities.

2/3,AB/6 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

11988299 EMBASE No: 2003098739
Autologous haematopoietic stem cell transplantation in juvenile idiopathic arthritis
Wedderburn L.R.; Abinun M.; Palmer P.; Foster H.E.
Dr. L.R. Wedderburn, Rheumatology Unit, Institute of Child Health, 30 Guilford Street, London WC1N 1EH United Kingdom
AUTHOR EMAIL: l.wedderburn@ich.ucl.ac.uk
Archives of Disease in Childhood (ARCH. DIS. CHILD.) (United Kingdom)
01 MAR 2003, 88/3 (201-205)
CODEN: ADCHA ISSN: 0003-9888
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 46

2/3,AB/7 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

11838118 EMBASE No: 2002410807
Treatment of Crohn's disease - The new era
Jewell D.P.
Prof. D.P. Jewell, Gastroenterology Unit, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE United Kingdom

Digestive and Liver Disease (DIG. LIVER DIS.) (Italy)
01 OCT 2002,
34/1 (689-691)
CODEN: DLDIF ISSN: 1590-8658
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 12

2/3,AB/8 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

11633968 EMBASE No: 2002205544
Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients
Halle P.; Paillard C.; D'Incan M.; Bordigoni P.; Piguet C.; De Lumley L.;
Stephan J.L.; Berger M.; Rapatel C.; Demeocq F.; Kanold J.
J. Kanold, U. Bioclin. de Therapie Cellulaire, Serv. d'Hematol./d'Oncol.
Pediat., Hotel Dieu, 11, Boulevard Leon Malfreyt, 63003 Clermont-Ferrand
France
AUTHOR EMAIL: jkanold@chu-clermontferrand.fr
Journal of Hematotherapy and Stem Cell Research (J. HEMATOTHER. STEM CELL RES.) (United States) 2002, 11/3 (501-512)
CODEN: JHERF ISSN: 1525-8165
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 35

A total of 254 extracorporeal photochemotherapy (ECP) procedures were performed in 8 children (median age 10 years; range 5-15) with extensive resistant chronic graft-versus-host disease (GVHD). ECP was carried out in the pediatric environment using a Cobe Spectra separator and UV-MATIC irradiator. A peripheral venous with a single-lumen permanent central catheter access (69% of ECP- *apheresis*) or a dual-lumen permanent central catheter access (26% of ECP- *apheresis*) were used preferentially. A median platelet decrease of 17% (0-71) (p = 0.0001) and median hemoglobin level decrease of 15 g/L (0-31) (p = 0.0001) were noted following each ECP- *apheresis*. However, none of the patients had profound thrombocytopenia or anemia. Two minor episodes of catheter

related-bacteremia (*Staphylococcus aureus*) were noted (2310 catheter-days). A negative correlation was found between lymphocyte collection efficacy (median = 38%) and pre ECP-*apheresis* lymphocyte count ($r = 0.4$, $p = 0.00001$). The median of 5×10^5 lymphocytes/kg (0.1-50.105UP7/kg) was irradiated in each procedure. All patients are alive and well, and 7/8 experienced a dramatic improvement in their cutaneous status. Liver and gut disease resolved completely in 4/6 and 5/5 patients, respectively. In all patients, a concomitant immunosuppressive therapy was stopped (5/8) or considerably reduced (3/8). Five patients with more than 2 years follow-up after discontinuation of ECP are in remission with no immunosuppression treatment. They have normal growth rates and normal school and sport activity. Our study shows that ECP is beneficial, well tolerated, and can be safely used for chronic GVHD treatment even in young children with low body weight and a poor performance status. We believe that having a dedicated pediatric environment together with an experienced, motivated, and specifically pediatric team is of crucial importance for improving patient's acceptance of this long-term therapeutic program.

2/3,AB/9 (Item 7 from file: 73)
 DIALOG(R)File 73:EMBASE
 (c) 2004 Elsevier Science B.V. All rts. reserv.

11617121 EMBASE No: 2002188728
 Juvenile dermatomyositis: Recognition and treatment
 Reed A.M.; Lopez M.
 Dr. A.M. Reed, Division of Rheumatology, Mayo Clinic, 200
 First Street
 SW, Rochester, MN 55905 United States
 AUTHOR EMAIL: reed.ann18@mayo.edu
 Paediatric Drugs (PAEDIATR. DRUGS) (New Zealand)
 2002, 4/5 (315-321)
 CODEN: PTDGF ISSN: 1174-5878
 DOCUMENT TYPE: Journal ; Review
 LANGUAGE: ENGLISH SUMMARY LANGUAGE:
 ENGLISH
 NUMBER OF REFERENCES: 56

Juvenile dermatomyositis (JDM) is a multisystem disease characterized by

acute and chronic lymphocytic inflammation of the skeletal muscle and skin.

The disease is marked early in its course by the presence of a vasculopathy or vasculitis, and later by the development of calcinosis. Research has focused on the epidemiology, etiology, and pathogenesis of the disease with, until more recently, limited therapeutic interventions. This article highlights treatment regimens, both traditional and more recent interventions. Traditional treatment for JDM includes high dose corticosteroid treatment with additional agents used in resistant disease or children with unwarranted adverse effects. Traditional therapy begins with daily oral corticosteroids, with intravenous corticosteroids utilized in severe disease; however, recent data suggests that short-term use of intravenous corticosteroids will allow a short-term improvement in strength, with no long-term change in outcome. More recent investigations suggest that early intervention with additional immunomodulatory agents will allow for a faster recovery, with less medication and disease sequelae. Use of methotrexate as an agent early in the disease course is becoming common place. Methotrexate, in conjunction with oral corticosteroids, allows a rapid improvement in symptoms, and allows for a more rapid reduction in corticosteroid dose. Methotrexate is considered as a steroid sparing agent, whether oral or intravenous corticosteroids are used. Additional immunomodulatory agents include the use of cyclosporine with or without methotrexate. Intravenous immunoglobulin has been reported to have benefit in resistant disease. There are exciting new agents which have great potential in treating JDM. Many of these agents are termed biologics and are being tested in adult myositis and juvenile arthritis. These include tumor necrosis factor (TNF)-alpha inhibitors, such as a chimeric monoclonal antibody to TNF-alpha, and a recombinant soluble human TNF receptor (p75)-Fc fusion protein. Many other new biological agents are also being tested in myositis.

2/3,AB/10 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

11581900 EMBASE No: 2002153316
Editorial overview: Clinical therapeutics
Arend W.P.
Dr. W.P. Arend, Division of Rheumatology, Univ. Colorado
Hlth. Sci. Ctr.
B115, 4200 East Ninth Avenue, Denver, CO 80262 United
States
AUTHOR EMAIL: william.arend@uchsc.edu
Current Opinion in Rheumatology (CURR. OPIN.
RHEUMATOL.) (United States
) 2002, 14/3 (201-203)
CODEN: CORHE ISSN: 1040-8711
DOCUMENT TYPE: Journal ; Editorial
LANGUAGE: ENGLISH

2/3,AB/11 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

11241844 EMBASE No: 2001256103
A clinical and economic review of disease-modifying
antirheumatic drugs
Gabriel S.E.; Coyle D.; Moreland L.W.
Dr. S.E. Gabriel, Mayo Foundation, 200 First St SW,
Rochester, MN 55905
United States
AUTHOR EMAIL: gabriel.sherine@mayo.edu
PharmacoEconomics (PHARMACOECONOMICS) (New
Zealand) 2001, 19/7
(715-728)
CODEN: PARME ISSN: 1170-7690
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE:
ENGLISH
NUMBER OF REFERENCES: 150

Rheumatoid arthritis is one of the most common chronic
systemic
inflammatory diseases, affecting approximately 1% of the
adult population.
Disease-modifying antirheumatic drugs (DMARDs) have
been the mainstay of
treatment for rheumatoid arthritis when combined with
physical therapy and
aspirin (acetylsalicylic acid) or nonsteroidal anti-
inflammatory drugs.
Recently, a number of new biological therapies have been
introduced for the
treatment of this condition and will have a major impact on
the future
management of this disabling disease. In this review, we
summarise data on

the efficacy and tolerability of the currently available
DMARDs, including
gold compounds, antimalarials, penicillamine, cytotoxic
drugs (azathioprine
and cyclophosphamide), sulfasalazine, methotrexate,
leflunomide,
cyclosporin, anti-tumour necrosis factor agents,
combination therapy and
apheresis. A literature review and quality assessment of
economic
evaluations of DMARDs is presented, illustrating that
there has been a
paucity of economic evaluations on these agents and
showing the variable
quality of those studies that are available. The manuscript
also addresses
the pharmacoeconomic implications of the new agents for
rheumatoid
arthritis; the need for formal long term economic
evaluations in order to
determine the cost effectiveness of these costly, but
highly effective, new
treatments is emphasised.

2/3,AB/12 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

11226302 EMBASE No: 2001240703
Arthritis therapy: A better time, a better day
Roth S.H.
S.H. Roth, Aging and Arthritis Program, Graduate
Colleges, Arizona State
University, Tempe, AZ United States
Rheumatology (RHEUMATOLOGY (UK)) (United
Kingdom) 2001, 40/6
(603-606)
CODEN: RUMAF ISSN: 1462-0324
DOCUMENT TYPE: Journal ; Editorial
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 30

2/3,AB/13 (Item 11 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

07909244 EMBASE No: 1999382552
New therapeutic approaches for rheumatoid arthritis
Abdelaty E.M.; Schumacher H.R. Jr.
Dr. H.R. Schumacher Jr., Arthritis-Immunology Center,
151 K, VAMC,
University and Woodland Avenues, Philadelphia, PA 19104
United States
International Journal of Clinical Practice (INT. J. CLIN.
PRACT.) (
United Kingdom) 1999, 53/7 (535-539)

CODEN: IJCPF ISSN: 1368-5031

DOCUMENT TYPE: Journal; Short Survey

LANGUAGE: ENGLISH SUMMARY LANGUAGE:
ENGLISH

NUMBER OF REFERENCES: 26

Better understanding of the immunopathogenesis of rheumatoid arthritis over the past few decades has promoted the innovation of new therapeutic approaches targeting the disease more specifically. In addition, refinements in the non-steroidal anti-inflammatory drugs (NSAID) may offer advantages for patients with RA. This brief review reports and analyses some of the important aspects of these new therapies available for treatment of RA and in which situations you might consider each. Before using any of these agents, physicians should become thoroughly familiar with the package inserts.

?

? s extracorporeal (5n)(infliximab or etanercept)

42726 EXTRACORPOREAL

4228 INFlixIMAB

2611 ETANERCEPT

S3 2 EXTRACORPOREAL (5N)(INFlixIMAB OR
ETANERCEPT)

? s s3 not s2

2 S3

13 S2

S4 2 S3 NOT S2

? t s4/3,ab/1,2

4/3,AB/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12256872 PMID: 12603689

Steroid-refractory graft-vs.-host disease: past, present and future.

Carpenter Paul A; Sanders Jean E

Fred Hutchinson Cancer Research Center and
University of Washington,

Department of Pediatrics, Seattle, WA 98109, USA.

Pediatric transplantation (Denmark) 2003, 7 Suppl 3
p19-31, ISSN

1397-3142 Journal Code: 9802574

Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Despite current standard preventive strategies that include optimizing donor selection and the combination of methorexate and a calcineurine

inhibitor, acute and chronic GVHD remains a major barrier to successful hematopoietic cell transplantation for a sizeable proportion of patients.

When acute and chronic GVHD become manifest a standard primary therapy approach has been the addition of glucocorticoid therapy to a background of calcineurine inhibition. When this approach fails patients with GVHD require secondary therapy. Ideally, second-line agents should promote transplantation tolerance so that the morbidity associated with prolonged use of glucocorticoids and other immunosuppressive agents can be minimized.

Promising new agents or strategies which warrant further controlled clinical trials include: mycophenolate mofetil, sirolimus, humanized or chimeric monoclonal antibodies such as visilizumab, daclizumab and *infiximab*, and *extracorporeal* photopheresis. Co-operative studies are necessary to hasten the process of evaluating novel treatment strategies for acute and chronic GVHD.

4/3,AB/2 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2004 Elsevier Science B.V. All rts. reserv.

12001984 EMBASE No: 2003113336

Steroid-refractory graft-vs.-host disease: Past, present and future

Carpenter P.A.; Sanders J.E.

P.A. Carpenter, Fred Hutchinson Cancer Res. Center,
University of

Washington, Department of Pediatrics, Seattle, WA
98109 United States

Pediatric Transplantation (PEDIATR. TRANSPLANT.)
(United Kingdom)

2003, 7/SUPPL. 3 (19-31)

CODEN: PETRF ISSN: 1397-3142

DOCUMENT TYPE: Journal ; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE:
ENGLISH

NUMBER OF REFERENCES: 81

Despite current standard preventive strategies that include optimizing donor selection and the combination of methorexate and a calcineurine inhibitor, acute and chronic GVHD remains a major barrier to successful hematopoietic cell transplantation for a sizeable proportion of patients.

When acute and chronic GVHD become manifest a standard primary therapy approach has been the addition of glucocorticoid therapy to a background of calcineurine inhibition. When this approach fails patients with GVHD require secondary therapy. Ideally, second-line agents should promote transplantation tolerance so that the morbidity associated with prolonged use of glucocorticoids and other immunosuppressive agents can be minimized.

Promising new agents or strategies which warrant further controlled clinical trials include: mycophenolate mofetil, sirolimus, humanized or chimeric monoclonal antibodies such as visilizumab, daclizumab and *infiximab*, and *extracorporeal* photopheresis. Co-operative studies are necessary to hasten the process of evaluating novel treatment strategies for acute and chronic GVHD.

? s extracorporeal/ti and (infiximab or etanercept)/ti

15185 EXTRACORPOREAL/TI

1206 INFILIXIMAB/TI

542 ETANERCEPT/TI

S5 0 EXTRACORPOREAL/TI AND (INFILIXIMAB OR ETANERCEPT)/TI

? s (infiximab or etanercept)/ti

1206 INFILIXIMAB/TI

542 ETANERCEPT/TI

S6 1684 (INFILIXIMAB OR ETANERCEPT)/TI

? s s6 and pd>20001110

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

1684 S6

1632830 PD>20001110

S7 751 S6 AND PD>20001110

? s s6 not s7

1684 S6

751 S7

S8 933 S6 NOT S7

? s s8 and extracorporeal

933 S8

42726 EXTRACORPOREAL

S9 0 S8 AND EXTRACORPOREAL

? s s8 and affinity adj chromatography

933 S8

0 AFFINITY ADJ CHROMATOGRAPHY

S10 0 S8 AND AFFINITY ADJ

CHROMATOGRAPHY

? s s8 and affinity

933 S8

368815 AFFINITY

S11 4 S8 AND AFFINITY

? t s11/3,ab/all

11/3,AB/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

15841502 PMID: 14632813

Infiximab for hidradenitis suppurativa.

Sullivan T P; Welsh E; Kerdel F A; Burdick A E; Kirsner R S

Department of Dermatology and Cutaneous Surgery, University of Miami

School of Medicine/Cedars Medical Center, 1400 NW 12th Ave. 6 South

Dermatology, Miami, FL 33136, USA.

British journal of dermatology (England) Nov 2003; 149 (5) p1046-9,

ISSN 0007-0963 Journal Code: 0004041

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic disease

characterized by significant morbidity. Current medical therapies are only

minimally effective at treating the disease. Infiximab is a chimeric

monoclonal antibody with high *affinity* for tumour necrosis factor

(TNF)-alpha. TNF-alpha is known to induce

proinflammatory cytokines and may

play an important role in the therapy of a number of disparate inflammatory

disorders. Infiximab has shown promise for the

therapy of rheumatoid

arthritis and psoriasis. OBJECTIVES: Retrospectively to evaluate the

effectiveness of infiximab for the treatment of HS. METHODS: A

retrospective chart review was performed for patients who received

infiximab at the University of Miami Department of Dermatology. Patients

were contacted and asked retrospectively to rate their disease activity

immediately prior to and after therapy. RESULTS:

Patients' self-reported

disease activity scores were significantly decreased (P = 0.0001, paired

t-test) following infiximab infusion. This correlated with

physician-observed clinical improvement.

CONCLUSIONS: Infiximab is a promising agent for the treatment of HS. These initial results suggest that

infiximab is associated with objective and subjective improvement in HS.

Further controlled studies of the efficacy of infiximab and its effect on

the course of the disease are warranted.

11/3,AB/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

15008454 PMID: 12110154
How does *infliximab* work in rheumatoid arthritis?
Maini Ravinder N; Feldmann Marc
The Kennedy Institute of Rheumatology Division,
Imperial College of
Science Technology and Medicine, London, UK.
r.maini@ic.ac.uk
Arthritis research (England) 2002, 4 Suppl 2 pS22-8,
ISSN 1465-9905
Journal Code: 100913255
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: In Data Review
Since the initial characterization of tumor necrosis
factor alpha
(TNFalpha), it has become clear that TNFalpha has
diverse biologic
activity. The realization that TNFalpha plays a role in
rheumatoid
arthritis (RA) has led to the development of anti-TNF
agents for the
treatment of RA. Infliximab, a chimeric monoclonal
antibody that
specifically, and with high *affinity*, binds to
TNFalpha and
neutralizes the cytokine, is currently approved for the
treatment of RA and
Crohn's disease, another immune-inflammatory disorder.
In addition to
establishing the safety and efficacy of infliximab, clinical
research has
also provided insights into the complex cellular and
cytokine-dependent
pathways involved in the pathophysiology of RA,
including evidence that
supports TNFalpha involvement in cytokine regulation,
cell recruitment,
angiogenesis, and tissue destruction.

11/3,AB/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

12055469 PMID: 12379627
Infliximab treatment for rheumatic disease:
clinical and
radiological efficacy.
St Clair E W

Department of Medicine, Division of Rheumatology, Duke
University Medical
Center, Durham, NC, USA. stcla003@mc.duke.edu
Annals of the rheumatic diseases (England) Nov
2002, 61 Suppl 2
pii67-9, ISSN 0003-4967 Journal Code: 0372355
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Infliximab is a chimeric anti-tumour necrosis factor
alpha (TNFalpha)
monoclonal antibody with high *affinity* and binding
specificity for
human TNFalpha. Results from several well designed,
controlled clinical
trials show repeated infusions of infliximab with
concomitant methotrexate
(MTX) treatment can reduce the signs and symptoms of
rheumatoid arthritis
(RA). This combination of infliximab and MTX also slows
the radiological
progression of joint damage, decreases functional
disability, and improves
quality of life. These remarkably positive results have
led to the
investigation of infliximab treatment for other
rheumatic diseases.
Recently, controlled studies have shown treatment with
infliximab can
benefit patients with active spondyloarthropathy.
TNFalpha has fast become
an important therapeutic target in rheumatology.

11/3,AB/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

11367282 PMID: 11458980
Immunomodulatory effects of *etanercept* (TNFR:Fc)
and its use in a
patient with Crohn's disease.
Srivastava M D
Department of Pediatrics, MetroHealth Medical
Center, Cleveland, Ohio
44109, USA.
Research communications in molecular pathology and
pharmacology (United
States) Jul 2001, 109 (1-2) p125-41, ISSN 1078-
0297 Journal Code:
9437512
Document type: Case Reports; Clinical Trial; Journal
Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Designer drug etanercept (TNFR:Fc) is an inhibitor of TNF-alpha that binds with greater *affinity* than membrane receptors. Its full immunomodulatory effects are unknown. Approved for rheumatoid arthritis, its therapeutic potential in Crohn's disease has yet to be explored. We describe the course of a steroid-dependent patient with Crohn's disease given etanercept, and its effects on cytokine protein and mRNA expression and transcription factor activity in human leukocytes. Etanercept 25 mg s.c., was given twice weekly for 1 month. Weekly ESR, disease activity index, prednisone requirement, and serum cytokines were determined. In vitro, effects of physiologic concentrations of etanercept on cytokine protein and mRNA, and NFkB and GR transcription factor activity, were determined using MOT and U937 cell lines and peripheral blood mononuclear cells. Rapid clinical, biochemical, and immunologic improvement occurred, but obstruction due to stricture developed after 4 weeks. In vitro, constitutive and stimulated production of TNF-beta, IL-1beta, MIP-1beta, and IL-8 by normal mononuclear cells declined with etanercept, detectable TNF-alpha increased. MOT TNF-alpha expression tripled, mRNA for IL-12 p40 doubled, GR activity declined in U937 cells, NFkB was unaffected. Etanercept has complex immunomodulatory effects, and may be useful in Crohn's disease, but acutely decreased inflammation could worsen stricture.

? ds

Set	Items	Description
S1	14	(ETANERCEPT OR INFLIXIMAB) AND APHERESIS
S2	13	RD (unique items)
S3	2	EXTRACORPOREAL (5N)(INFLIXIMAB OR ETANERCEPT)
S4	2	S3 NOT S2
S5	0	EXTRACORPOREAL/TI AND (INFLIXIMAB OR ETANERCEPT)/TI
S6	1684	(INFLIXIMAB OR ETANERCEPT)/TI
S7	751	S6 AND PD>20001110
S8	933	S6 NOT S7
S9	0	S8 AND EXTRACORPOREAL
S10	0	S8 AND AFFINITY ADJ CHROMATOGRAPHY
S11	4	S8 AND AFFINITY

? s s6 and immobilized/ti
 1684 S6
 11263 IMMOBILIZED/TI
 S12 0 S6 AND IMMOBILIZED/TI
 ? logoff
 01jul04 11:58:54 User217743 Session D640.5
 \$0.94 0.293 DialUnits File155
 \$1.47 7 Type(s) in Format 4 (UDF)
 \$1.47 7 Types
 \$2.41 Estimated cost File155
 \$11.39 1.162 DialUnits File73
 \$13.50 5 Type(s) in Format 3 (UDF)
 \$18.90 7 Type(s) in Format 4 (UDF)
 \$32.40 12 Types
 \$43.79 Estimated cost File73
 OneSearch, 2 files, 1.456 DialUnits FileOS
 \$1.25 TELNET
 \$47.45 Estimated cost this search
 \$57.73 Estimated total session cost 3.369 DialUnits
 Logoff: level 04.11.00 D 11:58:54